Celgene to acquire Avila Therapeutics for $350m plus $575m in milestones
This article was originally published in Scrip
Celgene is to acquire Avila Therapeutics, a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, for $350 million in cash, plus up to $195 million for milestones related to its lead product candidate, and a further $380 million in milestones related to the productivity of Avila's Avilomics platform.
You may also be interested in...
Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.